A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Anitocabtagene Autoleucel
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Pomalidomide
DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Daratumumab
DRUG: Carfilzomib

Sponsor

Kite, A Gilead Company

Collaborators

[object Object]